AnaptysBio raises $40m for Phase II studies

San Diego-based AnaptysBio has several antibody discovery partnerships with pharmaceutical and biotechnology companies, but the firm will use its $40m in Series D venture capital financing to run Phase II clinical trials for two of its own therapeutic candidates.

San Diego-based AnaptysBio has several antibody discovery partnerships with pharmaceutical and biotechnology companies, but the firm will use its $40m in Series D venture capital financing to run Phase II clinical trials for two of its own therapeutic candidates.

AnaptysBio's Phase II assets are an anti-Interleukin-33 (IL-33) antibody known as ANB020 for severe adult asthma and peanut allergy, and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category